Feed JAGX
JA

Jaguar Health

JAGX · NASDAQ

$7.70 -15.20% (-$1.38)
1M -36.63%
Market Cap $3.01M
P/E Ratio -
Div. Yield -
ROE -
Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Weak
3/9
Valuation
100 /100
Cheap
P/S 0.11x
P/B 0.61x
P/E N/A
Growth
14 /100
Declining
Rev. growth 1.26%
EPS growth N/A
Book val. growth N/A
Profitability
20 /100
Weak
Gross margin 82.28%
FCF margin 24.36%
Net margin 132.03%
Quality
15 /100
Poor
ROIC 118.21%
Asset turnover 0.81x
ROA 107.23%
Debt
4 /100
High
Debt/Equity 3.38x
Int. coverage -54.21x
Current ratio 0.69x
Stability
61 /100
Moderate
Beta -0.05x
Profitable years 0
Rev. volatility 19.10%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o JAGX
Online

O podjetju

Jaguar Health, Inc. (JAGX) is an American company focused on researching, developing, and commercializing pharmaceuticals and natural medicines for veterinary and human health. The company specializes in treating various gastrointestinal disorders, such as diarrhea and other digestive issues, in both animals and humans. Jaguar Health aims to utilize natural resources and innovative technologies to develop safe and effective therapeutic solutions. The company also has research projects focused on the prevention and treatment of other health conditions. Shares of Jaguar Health, Inc. (JAGX) can represent an interesting investment opportunity for investors who follow innovations in healthcare and pharmaceuticals and seek investments in the biotechnology sector.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Lisa A. Conte

Employees

47

Headquarters

San Francisco

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

46d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.